GlassScriptPhysician profile
Melissa M Kestler
NPI 1255988770
$5,120.38
in general payments reported to CMS, 2019-2025
29 companies · $1,032 in 2025
The $1,032 reported for 2025 was more than what 86% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $200 · 2022: $233 · 2023: $1,790 · 2024: $1,865 · 2025: $1,032.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,524 · Travel and Lodging: $1,037 · Education: $127.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,524.34 |
| Travel and Lodging | $1,036.71 |
| Education | $126.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,249.96 | 2022-2024 | Interstim |
| Axonics, INC. | $618.12 | 2024 | Axonics |
| Janssen Biotech, INC. | $568.58 | 2022-2025 | Erleada, Rybrevant, Carvykti |
| Bayer Healthcare Pharmaceuticals INC. | $526.12 | 2022-2025 | |
| Progenics Pharmaceuticals, INC. | $389.12 | 2023-2025 | Pylarify |
| Abbvie INC. | $370.63 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $215.74 | 2023-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Astellas Pharma US INC | $135.43 | 2023-2025 | Xtandi |
| Sumitomo Pharma America, INC. | $133.44 | 2023-2025 | Gemtesa, Orgovyx |
| Teleflex LLC | $105.72 | 2022-2024 | |
| Novartis Pharmaceuticals Corporation | $86.38 | 2023-2025 | |
| Endo USA, INC. | $81.03 | 2024-2025 | Aveed, Xiaflex |
| Olympus America INC. | $76.36 | 2023 | Itind System |
| Amgen INC. | $74.71 | 2021-2022 | |
| Coloplast Corp | $56.56 | 2024-2025 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $55.49 | 2023-2024 | Upsylon, Advantage System, Ams 800 Artificial Urinary Sphincter |
| Tempus Ai, INC | $49.31 | 2024-2025 | Xt Cdx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $48.71 | 2021 | |
| Accord Healthcare, INC. | $48.60 | 2023-2024 | |
| Dendreon Pharmaceuticals LLC | $46.34 | 2023 | Provenge |
| Astrazeneca Pharmaceuticals LP | $43.98 | 2021 | |
| Tolmar, INC. | $28.98 | 2023 | |
| Tolmar Pharmaceuticals, INC. | $24.49 | 2022 | |
| Myovant Sciences INC. | $16.47 | 2022 | |
| Novo Nordisk INC | $15.77 | 2021 | |
| Endo Pharmaceuticals INC. | $14.90 | 2024 | Xiaflex, Aveed |
| E.R. Squibb & Sons, L.L.C. | $14.26 | 2021 | |
| Pfizer INC. | $14.07 | 2021 | |
| Lilly USA, LLC | $11.11 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Kestler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.